Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 177

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Study of M9140 for Patients with Advanced Non-Small Cell Lung Cancer

Study of M9140 for Patients with Advanced Non-Small Cell Lung Cancer

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Study of M9140 for Patients with Advanced Stomach Cancer

Study of M9140 for Patients with Advanced Stomach Cancer

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Study on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Study of PRT3789 and Pembrolizumab for Patients with Advanced Solid Tumors, Esophageal Cancer, or NSCLC with SMARCA4 Mutation

Study of PRT3789 and Pembrolizumab for Patients with Advanced Solid Tumors, Esophageal Cancer, or NSCLC with SMARCA4 Mutation

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib